PCI device useful for IOL calculations

Article

A partial coherence interferometry (PCI) device has been found to be a valid tool for calculating toric intraocular lenses (IOL) in a recently published study.

A partial coherence interferometry (PCI) device has been found to be a valid tool for calculating toric intraocular lenses (IOL) in a recently published study.

Dr Mark A. Bullimore et al. (University of Houston, Texas, USA) examined the agreement between the IOLMaster 500 PCI device (Carl Zeiss Meditec) and the Marco 1-position manual keratometer (prospectively) and the Javal 2-position manual keratometer (retrospectively). Additionally, the repeatability of the PCI device was assessed.

When comparing the PCI device with the 1-position keratometer, the team found that the axis was within 5 degrees in 72.1% of eyes. There was a slight difference in the cyclinder power and the mean power of 0.18 D and 0.33 D respectively. The comparison of the PCI and the 2-position keratometer demonstrated similar results for the axis, which was within 5 degrees for 77.1% of eyes. The cylinder power was nearly the same, however the difference in mean power was 0.34 D. It was found that the repeatability of the PCI device was better than both manual options.

Based on these results, the team concluded that the agreement between the PCI device and the manual keratometers was excellent and therefore, the PCI device can be used for toric IOL calculations.

For further information please view the abstract in the Journal of Cataract & Refractive Surgery.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.